ORI Capital
Venture capital firm founded in 2015 that invests in early-stage life-sciences companies globally. Investment focus areas include diagnostics, drug delivery, and therapeutics with emphasis on high-mortality disease areas such as cancer, cardiovascular disease, and neurodegenerative disorders. The firm combines investment teams, scientific advisors and a data science capability to source, evaluate and support portfolio companies.
ORI Capital
Wan Chai, Hong Kong Island, Hong Kong, Asia
Services
Venture fund formation and management
Raising and managing life-sciences venture funds; capital deployment into early-stage biotech companies.
Scientific due diligence and advisory support
In-house scientific review and connection to external academic and clinical advisors to support technical evaluation and translational planning.
Data science and analytics for investment sourcing
Application of data-driven methods to identify and prioritize investment opportunities and monitor portfolio performance.
Venture fund formation and management
Raising and managing life-sciences venture funds; capital deployment into early-stage biotech companies.
Scientific due diligence and advisory support
In-house scientific review and connection to external academic and clinical advisors to support technical evaluation and translational planning.
Data science and analytics for investment sourcing
Application of data-driven methods to identify and prioritize investment opportunities and monitor portfolio performance.
Expertise Areas
- Life-sciences venture capital
- Scientific and technical due diligence
- Data science and AI for dealmaking
- Cell therapy and regenerative medicine
Key Technologies
- Induced pluripotent stem cell (iPSC)–derived cell therapies
- Cell therapy
- In vitro diagnostics (IVD) and tumor testing
- Gene therapy